PET Technology Review For Alzheimer's To Look At Prognostic Benefits
This article was originally published in The Gray Sheet
Executive Summary
HCFA's review of positron emission tomography imaging for Alzheimer's should take into account psycho-social benefits of the procedure in addition to its diagnostic capability, according to the executive committee (EC) of the Medicare Coverage Advisory Committee.
You may also be interested in...
PET Faces A No-Win Situation At MCAC Review Of Alzheimer’s Treatment
The Medicare Coverage Advisory Committee Diagnostic Imaging Panel's rejection of PET imaging for use in treating Alzheimer's disease demonstrates that diagnostic coverage reviews in the future may depend as much on the treatment in question as the diagnostic itself
PET Faces A No-Win Situation At MCAC Review Of Alzheimer’s Treatment
The Medicare Coverage Advisory Committee Diagnostic Imaging Panel's rejection of PET imaging for use in treating Alzheimer's disease demonstrates that diagnostic coverage reviews in the future may depend as much on the treatment in question as the diagnostic itself
AHRQ Alzheimer's Diagnosis Technology Assessment To Focus On PET
The Agency for Healthcare Research & Quality's technology assessment on Alzheimer's disease diagnosis should include a systematic review of positron emission tomography studies as well as literature citations for other imaging modalities, according to the Medicare Coverage Advisory Commission's executive committee.